Merck & Co Inc. MRK is permanently discontinuing its bacterial infection therapy Zinplava (bezlotoxumab) for commercial ...
“We were able to show that the natural compound argyrin B is highly effective against CDI: both in laboratory experiments and ...
A multi-omics study of lyophilized fecal microbiota transplantation and bacteria-free sterile fecal filtrate in recurrent ...
An open-label pilot trial found that a single fecal microbiota transplantation cleared adherent-invasive E. coli from the gut ...
WashU Medicine researchers have been awarded a nearly $11 million grant from the National Institute of Allergy and Infectious ...
A 2025 survey of NHS employees highlighted worrying variations in awareness of C difficile infection, risk factors and ...
Resplice Autism Research Foundation & Institute has opened its second Faecal Microbiota Transplantation (FMT) Centre in India ...
An antibiotic resistance gene helps a dangerous gut bacterium build tougher spores that can survive hospital disinfectants.
These findings provide new clinical evidence that LANCL2 activation may address inflammatory, metabolic and fibrotic processes associated with treatment refractoriness in IBD patients and support the ...
Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal (GI) ...
In a new study, researchers modeled the transmission of Clostridioides difficile (C. diff) infections among patients in hospital cancer units.
Acurx Pharmaceuticals (ISIN US00510M2035) remains tied to a USD 10.00 analyst target after Stock Analysis reported on September 30, 2026, that Alliance Global Partners reiterated its Buy rating and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results